Active ingredientNafamostatCat. No. P-N006-001CAS 81525-10-2Family · Pharmaceutical analytical standards
Nafamostat
A synthetic serine protease inhibitor developed in Japan, where it has been approved since 1986 for pancreatitis and since 1989 for disseminated intravascular coagulation and as an anticoagulant during dialysis. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Its half-life is about 8 minutes and dialysis itself removes it: so its anticoagulant effect stays concentrated almost entirely in the external circuit.
Go to the active ingredient →Active ingredientNafamostatCat. No. P-N006-001CAS 81525-10-2
Active ingredientNafamostat MesylateCat. No. P-N006-002CAS 82956-11-4
Isotopically labelledNafamostat-d4Cat. No. P-N006-003
Impurity2-Hydroxy-1-naphthonitrileCat. No. P-N006-004CAS 52805-47-7
Impurity2-Hydroxynaphthalene-1,6-dicarbonitrileCat. No. P-N006-005CAS 1416322-37-6
Impurity4,4'-Azoxydibenzoic acidCat. No. P-N006-006CAS 115325-88-7
Impurity4-((Aminocarbonyl)amino)benzoic acidCat. No. P-N006-007CAS 6306-25-8
ImpurityNafamostat Impurity 1Cat. No. P-N006-008CAS 2491698-53-2
Impurity4-Nitrosobenzoic acidCat. No. P-N006-009CAS 619-68-1
Impurity5,7-Dibromo-6-hydroxy-2-naphthonitrileCat. No. P-N006-010CAS 1235974-42-1
ImpurityNafamostat Impurity 2Cat. No. P-N006-011CAS 107490-62-0
Impurity6-Hydroxy-2-naphthamideCat. No. P-N006-012CAS 62529-01-5
Impurity7-Bromo-6-hydroxy-2-naphthonitrileCat. No. P-N006-013CAS 1192026-58-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.